C4-2 Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The C4-2 cell line is an androgen-independent human prostate cancer model derived from the parental LNCaP cell line. It was established through a stepwise in vivo selection process involving co-injection of LNCaP cells with human bone stromal cells (MS cells) into castrated immunodeficient mice, leading to the emergence of androgen-insensitive tumors. The C4-2 subline was specifically derived from the C4 variant after further passage in castrated hosts, and it retains the ability to grow and form tumors in androgen-depleted conditions without the need for stromal support. C4-2 cells maintain the prostate-specific antigen (PSA) production and expression of the androgen receptor (AR), including the characteristic T877A AR point mutation inherited from LNCaP, but display reduced androgen responsiveness compared to the parental line. While LNCaP cells require androgens for growth, C4-2 cells proliferate in androgen-depleted environments and continue to express PSA and AR-regulated genes, making them a robust model for castration-resistant prostate cancer (CRPC). In vitro, C4-2 cells grow more rapidly than LNCaP under standard culture conditions, and they also exhibit improved tumorigenicity in vivo. When injected subcutaneously into immunocompromised mice, C4-2 cells readily form tumors, a feature that contrasts with the slower or less consistent tumorigenic potential of LNCaP cells. The C4-2 model has been widely used to study mechanisms of resistance to androgen deprivation therapy (ADT), the role of intracrine androgen metabolism, and the molecular pathways underpinning CRPC progression. It retains expression of prostate-specific membrane antigen (PSMA), although at lower levels than LNCaP, and displays unique responses to androgen stimulation and antiandrogen therapies. These attributes make C4-2 a cornerstone model for evaluating new therapeutics targeting advanced prostate cancer. |
|---|---|
| 生物體 | Human |
| 組織 | Metastatic |
| 疾病 | Prostate carcinoma |
| 同義詞 | LNCaP-C4-2, LNCaP subline C4-2, C4-2, C42, Sp 2817 |
特徵
| 年齡 | 50 years |
|---|---|
| 性別 | Male |
| 族裔 | Caucasian |
| 形態學 | Epithelial-like |
| 生長特性 | Adherent |
監管數據
| 引用 | C4-2 (Cytion catalog number 305752) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_4782 |
生物分子資料
| 突變譜 | Mutation: AR, Simple, p.Thr878Ala (c.2632A>G), Hemizygous. Mutation, MEN1, Simple, p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A), Heterozygous (from parent cell line).Mutation, PIK3R1, Simple, p.Arg639Ter (c.1915C>T), Heterozygous (from parent cell line).Mutation, PTEN, Simple, p.Lys6Argfs*4 (c.17_18delAA), Unspecified (from parent cell line). |
|---|
處理方式
| 播種密度 | 2 - 3 x 104 cells/cm2 |
|---|---|
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305752-191125 | 分析證明書 | 08. Jan. 2026 | 305752 |